Molecular assessment of the tumor protein microenvironment using imaging mass spectrometry

Cancer Genomics and Proteomics

Volumn 3, Issue 5, 2006, Pages 279-287

  Caldwell, Robert L ^a,c   Gonzalez, Adriana ^a   Oppenheimer, Stacey R ^a   Schwartz, Herbert S ^b   Caprioli, Richard M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c Medical Center East   (United States)

Author keywords

Field effect; Imaging mass spectrometry; Tumor microenvironment

Indexed keywords

CALCYCLIN; KI 67 ANTIGEN; MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR PROTEIN;

ARTICLE; CANCER RECURRENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PROTEIN ANALYSIS; SOFT TISSUE SARCOMA;

EID: 33750816761     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Emrich LJ, Ruka W, Driscoll DL and Karakousis CP: The effect of local recurrence on survival time in adult high-grade soft tissue sarcomas. J Clin Epidemiol 42: 105-110, 1989.
2. Stotter AT, A'Hern RP, Fisher C, Mott AF, Fallowfield ME and Westbury G: The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer 65: 1119-1129, 1990.
3. Masasyesva BG, Tong BC, Brock MV, Pilkington T, Goldenberg D, Sidransky D, Harden S, Westra WH and Califano J: Molecular margin analysis predicts local recurrence after sublobar resection of lung cancer. Int J Cancer 773:1022-1025, 2005.
4. Ohori M, Wheeler TM, Kattan MW, Goto Y and Scardino PT: Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 154: 1818-1824, 1995.
5. Miller AR, Brandao G, Prihoda TJ, Hill C, Cruz AB Jr and Yeh IT: Positive margins following surgical resection of breast carcinoma: analysis of pathologic correlates. J Surg Oncol 86: 134-140, 2004.
6. Landheer ML, Klinkenbijl JH, Pasker-de Jong PC and Wobbes T: Residual disease after excision of non-palpable breast tumours: analysis of tumour characteristics. Eur J Surg Oncol 30: 824-828, 2004.
7. McKee MD, Liu DF, Brooks JJ, Gibbs JF, Driscoll DL and Kraybill WG: The prognostic significance of margin width for extremity and trunk sarcoma. J Surg Oncol 85: 68-76, 2004.
8. Kawaguchi N, Ahmed AR, Matsumoto S, Manabe J and Matsushita Y: The concept of curative margin in surgery for bone and soft tissue sarcoma. Clin Orthop Relat Res 419: 165-172, 2004.
9. Snyderman CH and D'Amico F: Outcome of carotid artery resection for neoplastic disease: a meta-analysis. Am J Otolaryngol 13: 373-380, 1992.
10. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR and Brakenhoff RH: A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 63: 1727-1730, 2003.
11. Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, Goodman SN and Sidransky D: Molecular assessment of histopathological staging in squamous-cel] carcinoma of the head and neck. N Engl J Med 332: 429-435, 1995.
12. van Houten VM, Leemans CR, Kummer JA, Dijkstra J, Kuik DJ, van den Brekel MW, Snow GB and Brakenhoff RH: Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin Cancer Res 10: 3614-3620, 2004.
13. Nathan CA, Amirghahari N, Abreo F, Rong X, Caldito G, Jones ML, Zhou H, Smith M, Kimberly D and Glass J: Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin Cancer Res 10: 5820-5827, 2004.
14. Nathan CA, Amirghahri N, Rice C, Abreo FW, Shi R and Stucker FJ: Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients. Laryngoscope 112: 2129-2140, 2002.
15. Fradet V, Lessard L, Begin LR, Karakiewicz P, Masson AM and Saad F: Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 10: 8460-8464, 2004.
16. Ananthanarayanan V, Deaton RJ, Yang XJ, Pins MR and Gann PH: Alphamethylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer. Prostate 63(4): 341-346, 2004.
17. Merrick DT, Haney J, Petrunich S, Sugita M, Miller YE, Keith RL, Kennedy TC and Franklin WA: Overexpression of vascular endothelial growth factor and its receptors in bronchial dypslasia demonstrated by quantitative RT-PCR analysis. Lung Cancer 48: 31-45, 2005.
18. Stoeckli M, Chaurand P, Hallahan DE and Caprioli RM: Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 7: 493-496, 2001.
19. Chaurand P, Schwartz S, Reyzer M and Caprioli R: Imaging mass spectrometry: principles and potentials. Toxicol Pathol 33: 92-101, 2005.
20. Caldwell RL and Caprioli RM: Tissue profiling by mass spectrometry: a review of methodology and applications. Mol Cell Proteomics 4: 394-401, 2005.
21. Stoeckli M, Staab D, Staufenbiel M, Wiederhold KH and Signor L: Molecular imaging of amyloid beta peptides in mouse brain sections using mass spectrometry. Anal Biochem 311: 33-39, 2002.
22. Aerni H-R. C, D. S and Caprioli RM: Automated acoustic matrix deposition for MALDI sample preparation. Anal Chem 78(3): 827-834, 2005.
23. Chaurand P, Schwartz SA, Billheimer D, Xu BJ, Crecelius A and Caprioli RM: Integrating histology and imaging mass spectrometry. Anal Chem 76: 1145-1155, 2004.
24. Reyzer ML, Caldwell RL, Dugger TC, Forbes JT, Ritter CA, Guix M, Arteaga CL and Caprioli RM: Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Cancer Res 64: 9093-9100, 2004.
25. Ham A-J, Jones JA and Liebler DC: CHIPS (Complete Hierarchical Integration of Protein Searches), a database program for storing, filtering and comparing Sequest outputs. Asms Conference Proceedings, Nashville, TN, USA, 2004.
26. Schwartz SA: Proteomic-based classification of human brain tumors by mass spectrometry. Edited by Nashville, Vanderbilt University, p. 139, 2004.
27. Chaurand P, Sanders ME, Jensen RA and Caprioli RM: Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. Am J Pathol 765: 1057-1068, 2004.
28. Campa MJ, Wang MZ, Howard B, Fitzgerald MC and Patz EF Jr: Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res 63: 1652-1656, 2003.
29. Reyzer ML, Hsieh Y, Ng K, Korfmacher WA and Caprioli RM: Direct analysis of drug candidates in tissue by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrom 38: 1081-1092, 2003.
30. Caldwell RL, Holt GE and Caprioli RM: Tissue profiling by MALDI mass spectrometry distinguishes clinical grades of soft tissue sarcomas. Cancer Gemomics and Proteomics 2: 333-346, 2005.
31. Crnogorac-Jurcevic T, Missiaglia E, Blaveri E, Gangeswaran R, Jones M, Terris B, Costello E, Neoptolemos JP and Lemoine NR: Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol 201: 63-74, 2003.
32. Komatsu K, Murata K, Kameyama M, Ayaki M, Mukai M, Ishiguro S, Miyoshi J, Tatsuta M, Inoue M and Nakamura H: Expression of S100A6 and S100A4 in matched samples of human colorectal mucosa, primary colorectal adenocarcinomas and liver metastases. Oncology 63:192-200, 2002.
33. Schafer BW, Wicki R, Engelkamp D, Mattei MG and Heizmann CW: Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome Iq21: rationale for a new nomenclature of the S100 calcium-binding protein family. Genomics 25: 638-643, 1995.
34. Donate R: S100: a multigenic family of calcium-modulated proteins of the EFhand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 33: 637-668, 2001.
35. Ott HW, Lindner H, Sarg B, Mueller-Holzner E, Abendstein B, Bergant A, Fessler S, Schwaerzler P, Zeimet A, Marth C and Illmensee K: Calgranulins in cystic fluid and serum from patients with ovarian carcinomas. Cancer Res 65: 7507-7514, 2003.
36. Ren Y, Tsui HT, Poon RT, Ng IO, Li Z, Chen Y, Jiang G, Lau C, Yu WC, Bacher M and Fan ST: Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer 107: 22-29, 2003.
37. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A and Bucala R: MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365: 756-759, 1993.
38. Calandra T, Bernhagen J, Mitchell RA and Bucala R: The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179: 1895-1902, 1994.
39. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A and Bucala R: MIF as a glucocorticoid-induced modulator of cytokine production. Nature 577: 68-71, 1995.
40. Mitchell RA and Bucala R: Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol 10: 359-366, 2000.
41. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ and Beach DH: A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190: 1375-1382, 1999.
42. Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M and Nishihira J: High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 264: 751-758, 1999.
43. Bini L, Magi B, Marzocchi B, Arcuri F, Tripodi S, Cintorino M, Sanchez JC, Frutiger S, Hughes G, Pallini V, Hochstrasser DF and Tosi P: Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 18: 2832-2841, 1997.
44. Meyer-Siegler K and Hudson PB: Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology 48: 448-452, 1996.
45. Kamimura A, Kamachi M, Nishihira J, Ogura S, Isobe H, Dosaka-Akita H, Ogata A, Shindoh M, Ohbuchi T and Kawakami Y: Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer 89: 334-341, 2000.
46. White ES, Strom SR, Wys NL and Arenberg DA: Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. J Immunol 166: 7549-7555, 2001.
47. Meyer-Siegler KL, Bellino MA and Tannenbaum M: Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer 94: 1449-1456, 2002.